- Home
- NPCT vs EDIT Comparison
NPCT vs EDIT Comparison
Compare NPCT & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCT
- EDIT
- Stock Information
- Founded
- NPCT 2020
- EDIT 2013
- Country
- NPCT United States
- EDIT United States
- Employees
- NPCT N/A
- EDIT N/A
- Industry
- NPCT Investment Managers
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NPCT Finance
- EDIT Health Care
- Exchange
- NPCT Nasdaq
- EDIT Nasdaq
- Market Cap
- NPCT 313.7M
- EDIT 263.7M
- IPO Year
- NPCT N/A
- EDIT 2016
- Fundamental
- Price
- NPCT $10.97
- EDIT $2.76
- Analyst Decision
- NPCT
- EDIT Buy
- Analyst Count
- NPCT 0
- EDIT 12
- Target Price
- NPCT N/A
- EDIT $5.40
- AVG Volume (30 Days)
- NPCT 107.1K
- EDIT 1.8M
- Earning Date
- NPCT 01-01-0001
- EDIT 11-03-2025
- Dividend Yield
- NPCT 9.82%
- EDIT N/A
- EPS Growth
- NPCT N/A
- EDIT N/A
- EPS
- NPCT N/A
- EDIT N/A
- Revenue
- NPCT N/A
- EDIT $38,901,000.00
- Revenue This Year
- NPCT N/A
- EDIT N/A
- Revenue Next Year
- NPCT N/A
- EDIT N/A
- P/E Ratio
- NPCT N/A
- EDIT N/A
- Revenue Growth
- NPCT N/A
- EDIT N/A
- 52 Week Low
- NPCT $8.58
- EDIT $0.91
- 52 Week High
- NPCT $10.63
- EDIT $4.12
- Technical
- Relative Strength Index (RSI)
- NPCT 54.26
- EDIT 54.04
- Support Level
- NPCT $10.80
- EDIT $2.39
- Resistance Level
- NPCT $10.94
- EDIT $2.72
- Average True Range (ATR)
- NPCT 0.11
- EDIT 0.18
- MACD
- NPCT 0.00
- EDIT -0.01
- Stochastic Oscillator
- NPCT 86.36
- EDIT 53.62
About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.